Novo Nordisk (NOVOB DC) reports triple agonist UBT251 delivers up to 19.7% mean weight loss after 24 weeks in phase 2 trial in China; The primary endpoint of the trial was the percentage change in body weight from baseline after 24 weeks of treatment

• “We are very encouraged by these data from the trial in China, which demonstrate the potential of UBT251 and its differentiated clinical profile and safety and tolerability profile,” said Martin Holst Lange, executive vice president, chief scientific officer and head of Research and Development at Novo Nordisk. “We look forward to reporting data from a global trial with UBT251 conducted by Novo Nordisk next year.”

Novo Nordisk's positive results from the phase 2 trial of UBT251, showing significant weight loss, could signal strong future performance for the company if this trend continues into global trials. The confirmation of safety and tolerability alongside these results adds to the therapy's attractiveness, which may bolster investor confidence and influence stock performance as the market anticipates further developments.